- Some people with colorectal cancer have a genetic mutation causing them to have an MMR deficient/MSI-High tumor.
- Past research shows that treating MMR deficient/MSI-High colorectal cancer tumors can sometimes be difficult.
- A new clinical trial has found that giving the immunotherapy drug pembrolizumab before surgery instead of chemotherapy can help improve outcomes for people with stage two or three MMR deficient/MSI-High colorectal cancer.
In 2020, more than
Read the full article here